Production plant that is a part of the new space obtained FDA okay.

Tris Pharma says that its facility expansion in South Brunswick, NJ, is complete. The company reports successful clearance of FDA preapproval inspection.

The expansion provides approximately 15,000 sq. ft. of additional space to the company’s premises and FDA-compliant cGMP facility.

It allows for additional commercial-scale equipment and a larger warehouse that frees up space for a high-speed packaging area. “FDA’s assurance of our facilities and the recent investment in our capabilities means we have ample infrastructure with which to leverage our exciting pipeline of drug delivery technologies and services,” says Ketan Mehta, CEO and founder of Tris Pharma.

Through its pharma partners, Tris reports that it has more than 30 products in development, submission, or on the market. The firm specializes in controlled-release dosage forms for liquid, solid, and orally disintegrating tablets as well as enhancing bioavailability of poorly absorbed drugs.

Previous articleInovio Wins $933K Biodefense Contract for DNA Vaccine Development
Next articleInvitrogen Initiates Stem Cell Culture Service